Edward Tenthoff
Stock Analyst at Piper Sandler
(2.73)
# 2,712
Out of 4,840 analysts
180
Total ratings
46.3%
Success rate
4.81%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Edward Tenthoff
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ITOS iTeos Therapeutics | Maintains: Overweight | $16 → $12 | $8.56 | +40.19% | 1 | May 14, 2025 | |
| ARVN Arvinas | Reiterates: Overweight | $24 → $14 | $6.51 | +115.05% | 7 | May 2, 2025 | |
| IPSC Century Therapeutics | Maintains: Overweight | $4 → $2 | $0.56 | +257.91% | 8 | Mar 20, 2025 | |
| DYN Dyne Therapeutics | Maintains: Overweight | $53 → $48 | $11.70 | +310.43% | 6 | Feb 28, 2025 | |
| MESO Mesoblast | Reiterates: Overweight | $15 → $24 | $10.83 | +121.71% | 5 | Feb 7, 2025 | |
| LEGN Legend Biotech | Reiterates: Overweight | $78 | $28.91 | +169.80% | 4 | Dec 30, 2024 | |
| XNCR Xencor | Upgrades: Overweight | $20 → $30 | $7.57 | +296.30% | 4 | Dec 2, 2024 | |
| ARWR Arrowhead Pharmaceuticals | Maintains: Overweight | $62 → $45 | $15.13 | +197.42% | 11 | Nov 27, 2024 | |
| ALNY Alnylam Pharmaceuticals | Reiterates: Overweight | $296 | $289.96 | +2.08% | 13 | Nov 18, 2024 | |
| MRNA Moderna | Reiterates: Overweight | $115 → $69 | $26.26 | +162.76% | 12 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $6 → $1 | $0.69 | +44.93% | 7 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $104 → $65 | $6.20 | +948.39% | 4 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $18 | $2.02 | +793.30% | 1 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $10.25 | +241.46% | 1 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $11 | $0.92 | +1,095.65% | 6 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $20 | $1.90 | +952.63% | 3 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $3 | $1.26 | +138.10% | 6 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8 → $3 | $0.66 | +353.58% | 4 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $16 | $3.99 | +301.51% | 3 | Jun 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $105 | $36.86 | +184.86% | 6 | Jun 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $4 → $6 | $1.17 | +412.82% | 7 | Jun 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $6 → $5 | $1.54 | +224.68% | 4 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $13 → $15 | $6.44 | +132.92% | 3 | Feb 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $39 → $56 | $29.50 | +89.83% | 4 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $31 | $1.23 | +2,420.33% | 5 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $90 | $3.10 | +2,803.23% | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $13 → $6 | $0.50 | +1,095.22% | 4 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $140 → $180 | $7.67 | +2,246.81% | 3 | Sep 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $37 → $44 | $18.20 | +141.76% | 1 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $76 → $37 | $8.06 | +359.34% | 2 | May 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $112,332 → $32,560 | $0.28 | +11,822,703.20% | 3 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $250 → $354 | $587.61 | -39.76% | 4 | Nov 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $105 → $135 | $1.13 | +11,846.90% | 2 | Sep 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $261 → $323 | $436.00 | -25.92% | 6 | Jul 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $33 → $36 | $42.39 | -15.07% | 2 | Feb 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $50 → $25 | $1.14 | +2,092.98% | 2 | May 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $150 | $0.81 | +18,372.91% | 1 | Jan 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $53 | $1.26 | +4,123.11% | 2 | Jan 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $1,380 | $0.64 | +214,719.43% | 1 | Dec 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $588.34 | - | 11 | Feb 13, 2017 |
iTeos Therapeutics
May 14, 2025
Maintains: Overweight
Price Target: $16 → $12
Current: $8.56
Upside: +40.19%
Arvinas
May 2, 2025
Reiterates: Overweight
Price Target: $24 → $14
Current: $6.51
Upside: +115.05%
Century Therapeutics
Mar 20, 2025
Maintains: Overweight
Price Target: $4 → $2
Current: $0.56
Upside: +257.91%
Dyne Therapeutics
Feb 28, 2025
Maintains: Overweight
Price Target: $53 → $48
Current: $11.70
Upside: +310.43%
Mesoblast
Feb 7, 2025
Reiterates: Overweight
Price Target: $15 → $24
Current: $10.83
Upside: +121.71%
Legend Biotech
Dec 30, 2024
Reiterates: Overweight
Price Target: $78
Current: $28.91
Upside: +169.80%
Xencor
Dec 2, 2024
Upgrades: Overweight
Price Target: $20 → $30
Current: $7.57
Upside: +296.30%
Arrowhead Pharmaceuticals
Nov 27, 2024
Maintains: Overweight
Price Target: $62 → $45
Current: $15.13
Upside: +197.42%
Alnylam Pharmaceuticals
Nov 18, 2024
Reiterates: Overweight
Price Target: $296
Current: $289.96
Upside: +2.08%
Moderna
Nov 18, 2024
Reiterates: Overweight
Price Target: $115 → $69
Current: $26.26
Upside: +162.76%
Nov 14, 2024
Downgrades: Neutral
Price Target: $6 → $1
Current: $0.69
Upside: +44.93%
Nov 13, 2024
Maintains: Overweight
Price Target: $104 → $65
Current: $6.20
Upside: +948.39%
Nov 5, 2024
Initiates: Overweight
Price Target: $18
Current: $2.02
Upside: +793.30%
Oct 21, 2024
Initiates: Overweight
Price Target: $35
Current: $10.25
Upside: +241.46%
Oct 11, 2024
Reiterates: Overweight
Price Target: $11
Current: $0.92
Upside: +1,095.65%
Sep 20, 2024
Reiterates: Overweight
Price Target: $20
Current: $1.90
Upside: +952.63%
Sep 17, 2024
Reiterates: Overweight
Price Target: $3
Current: $1.26
Upside: +138.10%
Jul 26, 2024
Maintains: Overweight
Price Target: $8 → $3
Current: $0.66
Upside: +353.58%
Jun 28, 2024
Reiterates: Overweight
Price Target: $16
Current: $3.99
Upside: +301.51%
Jun 17, 2024
Reiterates: Overweight
Price Target: $105
Current: $36.86
Upside: +184.86%
Jun 17, 2024
Upgrades: Overweight
Price Target: $4 → $6
Current: $1.17
Upside: +412.82%
Mar 5, 2024
Maintains: Overweight
Price Target: $6 → $5
Current: $1.54
Upside: +224.68%
Feb 28, 2024
Maintains: Overweight
Price Target: $13 → $15
Current: $6.44
Upside: +132.92%
Feb 27, 2024
Maintains: Overweight
Price Target: $39 → $56
Current: $29.50
Upside: +89.83%
Aug 14, 2023
Maintains: Overweight
Price Target: $28 → $31
Current: $1.23
Upside: +2,420.33%
Dec 12, 2022
Initiates: Overweight
Price Target: $90
Current: $3.10
Upside: +2,803.23%
Nov 4, 2022
Maintains: Overweight
Price Target: $13 → $6
Current: $0.50
Upside: +1,095.22%
Sep 7, 2022
Maintains: Overweight
Price Target: $140 → $180
Current: $7.67
Upside: +2,246.81%
Aug 25, 2022
Maintains: Overweight
Price Target: $37 → $44
Current: $18.20
Upside: +141.76%
May 23, 2022
Maintains: Overweight
Price Target: $76 → $37
Current: $8.06
Upside: +359.34%
May 13, 2022
Maintains: Overweight
Price Target: $112,332 → $32,560
Current: $0.28
Upside: +11,822,703.20%
Nov 29, 2021
Upgrades: Overweight
Price Target: $250 → $354
Current: $587.61
Upside: -39.76%
Sep 20, 2021
Maintains: Overweight
Price Target: $105 → $135
Current: $1.13
Upside: +11,846.90%
Jul 30, 2021
Maintains: Overweight
Price Target: $261 → $323
Current: $436.00
Upside: -25.92%
Feb 16, 2021
Maintains: Overweight
Price Target: $33 → $36
Current: $42.39
Upside: -15.07%
May 12, 2020
Downgrades: Neutral
Price Target: $50 → $25
Current: $1.14
Upside: +2,092.98%
Jan 27, 2020
Initiates: Overweight
Price Target: $150
Current: $0.81
Upside: +18,372.91%
Jan 6, 2020
Maintains: Overweight
Price Target: $26 → $53
Current: $1.26
Upside: +4,123.11%
Dec 11, 2017
Initiates: Overweight
Price Target: $1,380
Current: $0.64
Upside: +214,719.43%
Feb 13, 2017
Upgrades: Overweight
Price Target: n/a
Current: $588.34
Upside: -